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Abstract
Background: Early detection and treatment of asymptomatic men with advanced and
high-risk prostate cancer (PCa) may [10_TD$DIFF]improve survival rates.
Objective: To determine outcomes for men diagnosed with advanced PCa following
prostate-speciﬁc antigen (PSA) testing whowere excluded from the ProtecT randomised
trial.
Design, setting, and participants: Mortalitywas compared for 492men followed up for a
median of 7.4 yr [11_TD$DIFF]to a contemporaneous cohort of men from the UK Anglia Cancer
with a matched subset from the ACN.
nts and statistical analysis: PCa-speciﬁc and all-cause mortalityKeywords:
Prostate cancer
Network (ACN) and
Outcome measureme
were compared using Kaplan-Meier analysis and Cox’s proportional hazards regression.
ns: Of the 492 men excluded from the ProtecT cohort, 37 (8%) had
= 5, M1 = 32) and 305 had locally advanced disease (62%). The
g/l. Treatments included radical prostatectomy (RP; n = 54; 11%),Prostate-specific antigen
screening
Survival
Results and limitatio
metastases (N1, M0
median PSA was 17 m
radiotherapy (RT; n = 245; 50%), androgen deprivation therapy (ADT; n = 122; 25%),
other treatments (n = 11; 2%), and unknown (n = 60; 12%). There were 49 PCa-speciﬁc
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deaths (10%), of whom 14 men had received radical treatment (5%); and 129 all-cause
deaths (26%). In matched ProtecT and ACN cohorts, 37 (9%) and 64 (16%), respectively, died
of PCa, while 89 (22%) and 103 (26%) died of all causes. ProtecT men had a 45% lower risk of
death from PCa compared to matched cases (hazard ratio 0.55, 95% conﬁdence interval
0.38–0.83; p = 0.0037), but mortality was similar in those treated radically. The non-
randomised design is a limitation.
Conclusions: Men with PSA-detected advanced PCa excluded from ProtecT and treated
radically had low rates of PCa death at 7.4-yr follow-up. Among men who underwent
nonradical treatment, the ProtecT group had a lower rate of PCa death. Early detection
through PSA testing, leadtime bias, and group heterogeneity are possible factors in this
ﬁnding.
Patient summary: Prostate cancer that has spread outside the prostate gland without
causing symptoms can be detected via prostate-speciﬁc antigen testing and treated, leading
to low rates of death from this disease.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Population-based prostate specific antigen (PSA) screening
remains controversial [1]. Although screening in the
European Randomised Study of Screening for Prostate
Cancer (ERSPC) detected high numbers of prostate cancers
(PCas) and lower mortality from that disease, the majority
of cancers were indolent, leading to overdetection and
overtreatment [2,3]. The Prostate, Lung and Ovarian cancer
screening study (PCLO) reported no survival benefit after
11.5 yr of follow-up, but there was widespread contamina-
tion in the control armwith previous PSA testing (up to 90%)
[2,3].
There is uncertainty regarding the effectiveness of
treatments for PSA-detected clinically localised PCa. The
Prostate Cancer Intervention Versus Observation Trial
(PIVOT) reported no survival benefit after 12 yr of follow-
up among men with mainly low-risk disease treated with
surgery or observation, although there was high all-cause
mortality in both arms, suggesting that men with major
comorbidities were included [4]. No randomised trials have
compared different radical treatments for men with
advanced [5,6] or high-risk disease, and retrospective
studies have reported conflicting results [7–10]. There is
uncertainty regarding outcomes among [13_TD$DIFF] men with higher-
risk PCa detected via PSA screening, although a subgroup
analysis of PIVOT suggested benefit in favour of radical
treatment for intermediate- or high-risk disease [4].
Details of the ProtecT trial are reported elsewhere
[11–15]. Men with metastatic or locally advanced disease
(cT3–4) and/or PSA 20 mg/l were excluded from ProtecT,
along with men considered by local urologists to be
unsuitable for the trial because of their clinical features.
These men excluded from the ProtecT randomised trial but
diagnosed contemporaneously provide a unique opportu-
nity to assess the outcomes of advanced and high-risk
disease at diagnosis in a population with very low rates of
opportunistic PSA screening (8–13%) [12,16].
Here we present survival data for these men in
comparison to data for a contemporaneous cohort from
the UK Anglia Cancer Network (ACN), which has generally
low rates of PSA testing, and with a matched ACN cohort
with similar disease features.2. Patients and methods
2.1. Case population
The ProtecT trial compares active monitoring, conformal external-beam
radical radiotherapy (RT) with or without androgen deprivation therapy
(ADT) and radical prostatectomy (RP) treatments for PSA-detected
clinically localised PCa [12]. Between 2001 and 2009 there were 82 429
asymptomatic men aged 50 and 69 yr who underwent PSA testing, and
those with PSA 3 mg/l proceeded to biopsy. Participants with initial PSA
20 mg/l or found to have locally advanced (T3–4) PCa or distant disease
(N1 orM1)were ineligible and referred for standard care. Themajority had
locally advancedPCa; a small proportion (5%)wereclassedasathigh riskof
having non–organ-conﬁned disease and were felt to be unsuitable for
randomisation. In total, 513men (PSA20 mg/l, or locally advanced cT3–4
PCa, or Gleason 8, or N1/M1 disease) were excluded from ProtecT
(Table1).ThesemenformtheProtecTadvancedcasescohort reportedhere.
Information on treatment and survival was obtained during annual
ProtecT follow-up and checked using the English National Cancer Online
Registration Environment database in the Eastern Ofﬁce of the National
Cancer Registration Service (NCRS-E) [15]. Cause of death was
determined by review of certiﬁcation by two independent clinicians
blinded to study group and treatment.
2.2. Comparison population
Comparison patients (controls) were identiﬁed by the NCRS-E by
interrogation of the Anglia Cancer Network (ACN) [10] for a contempo-
rary cohort of men with comparable age and year of diagnosis and
similarly advanced and high-risk disease features: PSA 20 ng/ml,
locally advanced disease (cT3–4), Gleason score 8, or N1/M1
disease [4_TD$DIFF]. The ACN cases were judged to be a suitable comparative cohort
because of low rates of PSA testing (10–13%) in the ACN population
[12,17] (Supplementary material).
The ProtecT trial was approved by the East Midlands Ethics
Committee (Derby, UK; record number 01/4/025).
2.3. Statistical analysis
We used the x2 [9_TD$DIFF] test for heterogeneity to assess baseline differences
between cases and controls. The primary analysis compared risk of death
from PCa and all causes between ProtecT cases and ACN controls with
clinically detected PCa. Cases and controls were matched 1:1 according
to age, year of diagnosis, PSA, Gleason score, and clinical stage. Survival
estimates were carried out using Kaplan-Meier methods, with group
differences (unmatched andmatched) expressed as the hazard ratio (HR)
Table 1 – Demographic and clinicopathologic data for the study cohort
Variable Unmatched Matched
ProtecT ACN p value a ProtecT ACN p value a
Patients (n) 492 3978 401 401
Year of diagnosis, n (%) <0.0001 1
1999–2003 178 (36) 1109 (28) 151 (38) 151 (38)
2004–2006 191 (39) 1117 (28) 157 (39) 157 (39)
2007–2010 123 (25) 1752 (44) 93 (23) 93 (23)
Age band, n (%) <0.0002 0.86
50–59 yr 102 (21) 567 (14) 83 (21) 81 (20)
60–72 yr 390 (79) 3411 (86) 318 (79) 320 (80)
Serum PSA, n (%) <0.0001 0.48
<10 ng/ml 160 (33) 728 (18) 149 (37) 144 (36)
10–20 ng/ml 116 (24) 752 (19) 112 (28) 117 (29)
20–50 ng/ml 141 (28) 1086 (27) 90 (22) 75 (19)
50–100 ng/ml 49 (10) 462 (12) 24 (6) 30 (7)
>100 ng/ml 26 (5) 769 (19) 26 (6) 35 (9)
Unknown 0(0) 181 (5) 0 (0) 0 (0)
Mean PSA, ng/ml (median) 32.6 (16.7) 201.1 (26.5) 31.7 (14) 217.2 (13)
Gleason score, n (%) <0.0001 1
<7 112 (23) 473 (12) 93 (23) 92 (23)
7 259 (53) 1300 (33) 222 (55) 223 (55)
>7 115 (23) 1654 (42) 86 (21)) 86 (21)
Unknown 6 (10 551 (14) 0 (0) 0 (0)
Mean Gleason score (median) 7.1 (7) 7.6 (7) 7.1 (7) 7.0 (7)
Clinical stage, n (%) <0.0001 0.18
T1 17 (4) 989 (25) 16 (4) 29 (7)
T2 42 (8) 750 (19) 42 (10) 29 (7)
T3 305 (62) 1063 (27) 301 (75) 298 (74)
T4 5 (10 44 (1) 4 (1) 5 (1)
M1 or N1 37 (8) 1132 (28) 37 (9) 40 (10)
T stage unknown 86 (18) 0 (0) 1 (1) 0 (0)
Follow-up (yr)
Mean 7.5 5.5 7.7 7.5
Median 7.4 5 7.6 7.6
Interquartile range 5.5–9.7 3.1–7.8 5.5–9.8 5.1–9.8
ACN = Anglia Cancer Network; PSA = prostate-speciﬁc antigen.
a p value for x2 test for heterogeneity between unmatched and matched ProtecT advanced cases and ACN controls.
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Cox proportional hazards regression models (univariable and multivari-
able) were also ﬁtted to estimate survival for the unmatched ProtecT
cases and ACN controls adjusted for the above variables, with results
expressed as HR with 95% CI. A sensitivity Cox regression survival
analysis was performed for a subset of the unmatched groups separated
for N0M0 and N1 or M1 disease, and was also ﬁtted for the matched
groups with further adjustment for treatment allocation. Fisher’s exact
test and a two-sample z-test of proportions were used to assess
differences between treatments received in the matched groups. A
secondary analysis assessed biochemical-free and castrate-resistant–
free survival within treatment groups. Data for patients who died from
PCa or other causes were censored at date of death. All tests were two-
sided, with statistical signiﬁcance set at p < 0.05. All analyses were
performed using IBM SPSS for Windows, version 22.0, GraphPad Prism,
version 6, and STATA version 14.
3. Results
3.1. ProtecT case and ACN control characteristics
The flow of the patients through the study is summarised
in Figure 1. There were 513 ProtecT advanced cases, of
whom 21 were excluded because of incomplete data at
presentation. For the remaining 492 cases, themean agewas
64 yr (interquartile range [IQR] 61–68); median PSA was17 ng/ml (mean 33, IQR 8–32 ng/ml); 43% had PSA 20 ng/
ml; 62% had clinical stage T3; 23% had a Gleason score8;
and 8% had N1 or M1 disease. Median follow-up was 7.4 yr
(IQR 5.5–9.7; Table 1). For analysis of biochemical recur-
rence, data on primary treatment were available for 432 out
of 492 ProtecT cases (88%), and data on PSA follow-up and on
neoadjuvant, adjuvant, or salvage therapies for 352 out of
492 cases (72%).
We identified 3978 ACN controls aged 50–72 yr with
clinically detected PCa.Median follow-upwas 5 yr (IQR 3.1–
7.8). There were differences in baseline characteristics: ACN
controls were older, had higher PSA levels, higher Gleason
scores, and higher PCa stages (all p < 0.0002). Accordingly,
we matched ProtecT cases (n = 401) to ACN controls
(n = 401) across these variables (Table 1). The median
follow-up for the matched cohorts was 7.6 yr (IQR 5.1–9.8).
There were complete data on primary treatment for 352 of
401 (88%) matched ProtecT cases and 391 of 401 (98%) ACN
controls (Table 2).
3.2. Survival analysis
3.2.1. ProtecT advanced cases
Of the 492 ProtecTmen, 54 (11%) had radical prostatectomy
(RP); 245 (50%) had RT, of whom 93% had neoadjuvant and
[(Fig._1)TD$FIG]
Fig. 1 – Diagram of patient flow through study. KM = Kaplan-Meier; PSA = prostate-specific antigen.
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primary chemotherapy; six (1%) had other treatment (high-
intensity focused ultrasound or monitoring); and for 60
(12%) the treatment was unknown. We were unable to
demonstrate a difference in PCa-specific (HR 0.95, 95%
CI 0.22–4.12; p = 0.94) or all-cause mortality (HR 0.69, 95%
CI 0.29–1.67; p = 0.41) between the RP and RT groupsTable 2 – Primary treatments and death rates among matched ProtecT
Treatment Matched ProtecT cases
N Deaths, n (%)
PCS A
RP 47 1 (4) 2 (
RT + ADT a 200 11 (6) 31 (
Nonradical b 105 19 (18) 37 (
Unknown 49 6 (12) 19 (
Total 401 37 (9) 89 (
RP = radical prostatectomy; ADT = androgen deprivation therapy; PCS = prostate
a Adjuvant ADT was given in combination with radical radiotherapy in 93% of Pr
b Nonradical treatment includes primary ADT, palliative chemotherapy, palliativ(Fig. 2A [14_TD$DIFF],2B). Men who received RP were younger (p < 0.01)
and had lower PSA (p < 0.0001) compared to the RT group,
but no significant difference was observed in Gleason score
(p = 0.84) or stage (p = 0.19; Supplementary Table 1).
All-cause mortality was 7% (4/54) among men who
underwent RP (2 died of PCa; 4%) and 15% (37/245) among
those who received RT (12 died of PCa; 5%). All-causecases and Anglia Cancer Network (ACN) controls
Matched ACN controls
n Deaths, n (%)
C PCS AC
4) 150 5 (3) 12 (8)
16) 127 6 (5) 20 (16)
35) 114 51 (45) 68 (60)
38) 10 1 (10) 3 (3)
22) 401 63 (16) 103 (26)
cancer–speciﬁc; AC = all causes.
otecT cases and 88% of ACN controls.
e radiotherapy, and monitoring.
[(Fig._3)TD$FIG]
Fig. 3 – Kaplan-Meier plots of (A) prostate cancer–specific survival and
(B) overall survival among matched ProtecT cases and Anglia Cancer
Network (ACN) controls. By the end of the study, 37 matched cases (9%)
and 64 controls (16%) died from prostate cancer. Death from all causes
occurred in 89 cases (22%) and 103 controls (26%). HR = hazard ratio;
CI = confidence interval.
[(Fig._2)TD$FIG]
Fig. 2 – (A) Prostate cancer–specific survival and (B) overall survival
according to primary treatment groups among ProtecT cases. Death
from prostate cancer occurred in two (4%) of the RP and 12 (5%) of the
RT group (HR 0.95, CI 95% 0.22–4.12; p = 0.94). Death from all causes
occurred in four (7%) of the RP and 37 (15%) of the RT group (HR 0.69,
95% CI 0.29–1.67; p = 0.41). A significantly greater proportion of the ADT
group died from prostate cancer (n = 27, 22%) and all causes (n = 49,
40%) compared to men treated with radical therapy (p < 0.0001).
RP = radical prostatectomy; RT = radical radiotherapy; ADT = androgen
deprivation therapy; HR = hazard ratio; CI = confidence interval.
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radical treatment (51/133; 38%) andmenwhose treatments
were unknown (25/60; 42%; all p < 0.0001; Fig. 2A,2B).
Men treated using ADTwere older (p = 0.01) and had higher
PSA (p < 0.0001), Gleason score (p = 0.05), and stage
(p < 0.0001) compared to men who received radical
treatment (Supplementary Table 1).
3.2.2. Comparison with ACN controls: Kaplan-Meier survival
analysis
We found lower risks of death from PCa (HR 0.29, 95% CI
0.38–0.53; p < 0.0001) and from all causes (HR 0.45, 95% CI
0.48–0.63; p < 0.0001) among ProtecT cases compared to
unmatched ACN controls (Supplementary Fig. 1A [14_TD$DIFF],1B). After
matching (Table 1) we observed a 45% lower rate of death
from PCa (HR 0.55, 95% CI 0.38–0.83; p = 0.0037), but were
unable to demonstrate a difference in all-cause deaths (HR
0.83; 95% CI 0.63–1.1; p = 0.19) between matched ProtecT
cases and ACN controls at 7.6 yr (Fig. 3A,3B).
There was a similar proportion of men who received
radical and nonradical treatments in the matched groups(p = 0.87), but more men in the ProtecT group received RT
compared to the matched ACN controls (p < 0.0001;
Table 2).
Among the ProtecT matched cases, 247 men received
radical treatment (RP n = 47; RT n = 200) of whom 12 died
from PCa (RP n = 1 [4%]; RT n = 11 [6%]) and 33 died of all
causes [RP n = 2 [4%]; RT n = 31 [16%]).
Among the ACN matched controls, 277 men received
radical treatment (RP n = 150; RT n = 127) of whom 11 died
of PCa (RP n = 5 [3%]; RT n = 6 [5%]) and 32 died of all causes
(RP n = 12 [8%]; RT n = 20 [16%]).
Among[15_TD$DIFF] the matched men who received nonradical
treatment, a significantly greater proportion died in the
ACN control group (n = 114; 51 PCa deaths and 68 all-cause
deaths) than in the ProtecT group (n = 105; 19 PCa deaths
and 37 all-cause deaths; p < 0.0002; Table 2).
3.2.3. Comparison with ACN controls: Cox proportional hazards
survival analysis
Multivariable analysis for the unmatched groups revealed
that ProtecT cases (n = 404) had a 53% lower risk of death
from PCa (HR 0.47, 95% CI 0.34–0.66; p < 0.0001) and a 30%
lower risk of death from all causes (HR 0.70, 95% CI 0.56–
0.88; p < 0.0001) compared to unmatched ACN controls
(n = 3335; Table 3). Higher PSA, higher Gleason score, and
higher stage all indicated a greater risk of death, whereas
later years of diagnosis lowered the risk. There was also a
higher risk of death from all causes in the oldest age group
Table 3 – Cox proportional hazards survival analysis
Variable Reference Univariate analysis Multivariate analysis
category Prostate cancer–speciﬁc
survival
Overall survival Prostate cancer–speciﬁc
survival
Overall survival
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
ProtecT cases ACN controls 0.29 (0.21–0.38) <0.0001 0.45 (0.38–0.55) <0.0001 0.47 (0.34–0.66) <0.0001 0.70 (0.56–0.88) <0.002
Year of diagnosis 1999–2009
2004–2006 0.63 (0.55–0.72) <0.0001 0.71 (0.63–0.79) <0.0001 0.55 (0.46–0.65) <0.0001 0.69 (0.60–0.79) <0.0001
2007–2010 0.48 (0.41–0.58) <0.0001 0.55 (0.48–0.64) <0.0001 0.48 (0.38–0.60) <0.0001 0.59 (0.50–0.71) <0.0001
Age band 50–59 yr
60–66 yr 0.90 (0.75–1.07) 0.24 1.09 (0.93–1.28) 0.29 0.89 (0.71–1.10) 0.28 1.06 (0.88–1.29) 0.52
67–72 yr 1.12 (0.94–1.33) 0.20 1.56 (1.34–1.81) <0.0001 0.97 (0.79–1.19) 0.75 1.43 (1.19–1.71) <0.0001
PSA 0–10 ng/ml
10–20 ng/ml 1.23 (0.93–1.62) 0.14 1.37 (1.12–1.67) 0.002 1.05 (0.78–1.40) 0.76 1.22 (0.99–1.50) 0.065
20–50 ng/ml 1.58 (1.23–2.01) <0.0001 1.57 (1.31–1.89) <0.0001 1.48 (1.14–1.93) <0.003 1.52 (1.25–1.85) <0.0001
50–100 ng/ml 2.57 (1.97–3.36) <0.0001 2.20 (1.80–2.71) <0.0001 1.80 (1.35–2.43) <0.0001 1.66 (1.32–2.08) <0.0001
>100 ng/ml 8.38 (6.70–10.5) <0.0001 5.87 (4.93–6.98) <0.0001 2.65 (2.02–3.45) <0.0001 2.43 (1.96–2.98) <0.0001
Combined Gleason <7
7 1.39 (1.05–1.84) 0.02 1.04 (0.86–1.26) 0.68 1.66 (1.22–2.26) <0.001 1.18 (0.96–1.44) 0.12
>7 4.13 (3.18–5.36) <0.0001 2.47 (2.08–2.93) <0.0001 4.01 (3.0–5.37) <0.0001 2.45 (2.01–2.96) <0.0001
Clinical stage T1/T2
T3 0.71 (0.57–0.88) <0.002 0.70 (0.60–0.81) <0.0001 1.21 (0.96–1.53) 0.11 1.08 (0.92–1.29) 0.32
T4 2.10 (1.18–3.76) 0.01 1.51 (0.95–2.43) 0.08 2.74 (1.52–4.92) <0.001 1.96 (1.22–3.15) <0.005
M1 or N1 8.22 (7.08–9.55) <0.0001 4.88 (4.36–5.47) <0.0001 5.79 (4.82–6.95) <0.0001 3.53 (3.07–4.10) <0.0001
HR = hazard ratio; CI = conﬁdence interval; ACN = Anglia Cancer Network; PSA = prostate-speciﬁc antigen.
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did not demonstrate a difference in the risk of death from
PCa (HR 0.69, 95% CI 0.45–1.06; p = 0.09) or all causes (HR
0.94, 95% CI 0.73–1.22; p = 0.65) between the unmatched
groups. However, men with N1 or M1 disease had a much
lower risk of death from PCa (HR 0.33, 95% CI 0.18–0.59;
p < 0.0001) and all causes (HR 0.38; 0.22 - 0.63; P < 0.0001)
in the ProtecT group than in the ACN group (Supplementary
Table 2).
Multivariable analysis was performed for the matched
groups after further adjusting for treatment received. We
did not find evidence of a difference in the risk of death from
PCa among men who received radical treatment (HR 1.91,
95% CI 0.73–5.02; p = 0.19). Men treated with RT had a
higher risk of death from all causes compared to the RP
group (HR 2.02, 95% CI 1.08–3.77, p = 0.03). There was a
much higher risk of death from PCa (HR 6.70, 95% CI 2.64–
16.9; p < 0.0001) and all causes (HR 4.55, 95% CI 2.42–8.52;
p < 0.0001) amongmenwho received nonradical treatment
compared to those who underwent radical treatment
(Supplementary Table 3).
3.2.4. Kaplan-Meier analysis of biochemical recurrence by primary
treatment group in the ProtecT group
PSA follow-up was available for ProtecT cases and is
reported in more detail in the Supplementary material. At a
median of 7.4 yr, PCa-specific survival was 96% in the RP
group and 96% in the RT group. There were no predictors of
biochemical failure, PCa-specific mortality, or overall
mortality among men treated with RP or RT on univariable
or multivariable analysis, except for high Gleason score,
which increased the risk of death from all causes in the RT
group (HR 6.48, 95% CI 1.48–28.4; p = 0.01; Supplementary
Table 4 and Supplementary Fig. 2).4. Discussion
This study reports on asymptomatic men who were
excluded from ProtecT because of advanced and high-risk
PCa; their outcomes form an important component of the
overall context of the ProtecT study and its generalisability
with respect to treatment of PSA-detected PCa. [16_TD$DIFF] n men [17_TD$DIFF]who
were excluded from ProtecT[18_TD$DIFF], but [19_TD$DIFF]were [20_TD$DIFF]treated [21_TD$DIFF]radically, we
found low rates of all-cause and PCa [22_TD$DIFF] specific [23_TD$DIFF]deaths (14%
and 5%), with no differences between surgery and radio-
therapy [24_TD$DIFF] at a median of 7.4 years. Most deaths occurred
among men receiving nonradical treatments, probably
because they had more advanced disease and/or were not
fit for radical treatment, although very unfit men were
screened out from ProtecT by the general practitioner.
With respect to the main clinical outcome paper from
ProtecT, all-causemortality (10% at amedian of 10 yr) [[25_TD$DIFF]13]
was lower than that noted here in the RT group (15%). This
suggests that ProtecT men with advanced PCa treated by
RT in the present study were less fit than those in the
randomised group. Moreover, the group who received
nonradical treatment and those whose treatment was
unknown had significantly greater all-cause mortality (38%
and 42%, respectively) compared with those undergoing
radical treatment. The PCa-specific mortality among the
ProtecT group receiving radical treatment (5%) was greater
than that found in the randomised group (1%), but
nevertheless indicates very good cancer survival.
The reduction in risk of death from PCa among advanced
ProtecT cases (45%) compared to ACN controls persisted
after careful case-control matching to attempt to compen-
sate for leadtime bias and differences in baseline char-
acteristics. However, other biases cannot be ruled out,
including the greater number of men undergoing surgery in
E U RO P E AN URO L OGY 7 1 ( 2 0 1 7 ) 3 8 1 – 3 8 8 387the ACN group than in the ProtecT group when comparing
those who received radical treatment, and the fact that the
ACN group were generally less fit. However, there were no
differences in PCa-specific or all-cause mortality between
thematched cases and controls when comparing those who
received radical treatment. The higher death rates observed
among ACN controls occurred mainly in men who received
nonradical treatments, suggesting early detection may
improve the life expectancy of this subgroup, although
other explanations such as group heterogeneity, leadtime
bias, and selection bias cannot be ruled out.
Cox regression results for survival analysis (53% lower
risk of death from PCa and a 30% reduction in all-cause
mortality in the ProtecT group) can probably be explained in
part by leadtime bias in the ProtecT cohort [18,19].
We found no difference in PCa-specific or overall survival
between the RP and RT ProtecT groups. Only a small
proportion ofmenwho received radical treatment (RP 4%, RT
5%) died from PCa, which adds to increasing evidence that
radical treatment of locally advanced or high-risk disease
delivers good oncologic outcomes[8,9]. The all-cause and
PCa survival outcomes for the ProtecT group are better than
in most studies on men clinically presenting with advanced
disease [20], supporting the hypothesis that early detection
of advanced and high-risk PCa may be of benefit. The wider
context of the impact of PSA testing on community-based
men will be presented in the findings of the CAP (Cluster
randomised trial of prostate cancer) trial in 2017 [21].
The quality of data for the ACN group is likely to be good
[15,21].Weminimisedmisattribution of death by using two
independent clinicians blinded to the study group and
treatment, and by checking with the ProtecT recruitment
centre of origin. Matching reduced the number of men for
the matched analysis (n = 401) and there may be additional
biases that our matching process was unable to take into
account. Multidisciplinary teams reviewed the histopathol-
ogy for ACN controls, whereas ProtecT cases were reviewed
by the expert ProtecT histopathology group [22]. For
surgically treated ACN cases, however, histology was
reviewed centrally. Potential differences in grade and stage
allocation may have had some impact on apparent survival
benefits among the ProtecT cases. Therewas no information
available on the comorbidity burden for the ACN controls,
and therefore we were unable to match the two groups
according to these factors. ProtecT participants were 98%
Caucasian and patients with a prior history of cancer were
excluded, which may have influenced overall survival. The
natural history of PCa can be long and further follow-up is
required, but such leadtime factors are likely to be of lesser
magnitude among men with advanced disease [23–25].
5. Conclusions
PSA testing identifies asymptomatic men with advanced
and high-risk PCa whose early treatment leads to good
survival rates. [26_TD$DIFF]We [27_TD$DIFF]observed improved survival [28_TD$DIFF]in [29_TD$DIFF]the
ProtecT men who received nonradical treatment compared
to men presenting clinically without PSA testing [7_TD$DIFF], although
leadtime and selection bias are difficult to exclude. It will beimportant to assess longer-term survival and add patient-
reported outcomes among these men to assess the balance
between treatment impact and survival.
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